Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

Considering taking supplements to treat prurigo nodularis? Below is a list of common natural remedies used to treat or reduce the symptoms of prurigo nodularis. Follow the links to read common ...

The European Commission (EC) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The drug has been authorised for use in atopic dermatitis patients ...

Nemluvio’s approved indications include atopic dermatitis in patients aged 12 years and older and prurigo nodularis in adults. The approvals are supported by two phase 3 clinical trial programs.

IL-31 is a protein that drives itch and plays a role in inflammation and skin barrier dysfunction in both AD and prurigo nodularis and fibrosis in prurigo nodularis, the company states.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for nemolizumab (Nemluvio, Galderma) to treat moderate to severe prurigo nodularis in adults and ...

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas. 24-26 It is ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nemolizumab (brand name Nemluvio) for the treatment of two skins conditions – moderate to severe prurigo ...

Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...

showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis 1-3 There is a need for new treatment options for atopic ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...